Drummers, dancers, and speakers blasting Lady Gaga for a crowd of five hundred people linking hands and doing the wave is not the image typically conjured up when one hears of a World Health Organization event. A crowd gathered beneath a small stage decorated with slogans championing universal health coverage. Despite the morning’s chill lingering […] Continue reading ->
When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading ->
Hospitals in the Indian state of Rajasthan will be assessed next month to gauge whether upgrades, paid for with a new international innovative financing model, have brought them up to the new government quality standards. At least 92 small private healthcare organisations (SHCOs) - small private rural and urban hospitals - are being upgraded this year, and 360 in total over three years. If they manage to improve, 600,000 pregnant women would have improved care during delivery and potentially save the lives of up to 10,000 women and newborns over five years, according to one of the funders, the US government’s donor arm, USAID. The innovative financing model, called a development impact bond, has been put together by a consortium of philanthropic, NGOs, private organisations with USAID. But importantly, according to Priya Sharma, senior policy and innovative financing adviser at USAID, the model is advantageous for funders – whether they be governments or donors - wanting to make improvements with better outcomes. Continue reading ->
DAR ES SALAAM, Tanzania -- When Yusta Michael (not her real name) unintentionally fell pregnant in the first year of her university, she realised her dreams had been shattered. A hard-working student at the Institute of Social Welfare in Tanzania’s largest commercial city, Michael was aspiring to become a social worker and help addressing the plight of street children in the sprawling city. At three months pregnant, Michael decided to terminate the pregnancy because her boyfriend disowned it, and she didn’t want to disappoint her deeply religious parents. Continue reading ->
Some 60 percent more Africans die from cancer than malaria, and the number of cancer deaths is expected to increase almost 70% by 2030, according to experts. Breast, cervical, prostate, lymphoma and colorectal constitute the top five cancers diagnosed on the continent. In order to address this emerging cancer crisis, the African Access Initiative (AAI) was launched over a year ago. Continue reading ->
Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading ->
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading ->